Estradiol Cypionate

Low Testosterone, hypoestrogenism, Menopause + 1 more
Treatment
5 FDA approvals
7 Active Studies for Estradiol Cypionate

What is Estradiol Cypionate

Estradiol cypionateThe Generic name of this drug
Treatment SummaryEstradiol Cypionate is a form of the hormone estradiol, which is the most powerful type of estrogen found in humans. Estradiol Cypionate is used to treat a range of conditions related to low estrogen levels, such as menopausal symptoms, hypogonadism, and certain types of cancer. The medication is given as an intramuscular injection and works by binding to estrogen receptors in the body, which can help improve symptoms. Estradiol Cypionate is a bioidentical form of estrogen, meaning it is chemically identical to the hormone naturally produced in the body.
Depo-Estradiolis the brand name
image of different drug pills on a surface
Estradiol Cypionate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Depo-Estradiol
Estradiol cypionate
1979
2

Approved as Treatment by the FDA

Estradiol cypionate, also called Depo-Estradiol, is approved by the FDA for 5 uses like Hypogonadism and Menopause .
Hypogonadism
Helps manage Hypogonadism
Menopause
moderate Menopausal Vasomotor Symptoms
Low Testosterone
Helps manage Hypogonadism
hypoestrogenism
Helps manage hypoestrogenism

Effectiveness

How Estradiol Cypionate Affects PatientsEstrogen can have effects on different parts of the body, such as the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain. Its effects are caused by connecting to two types of receptors: Estrogen Receptor Alpha (ERα) and Estrogen Receptor Beta (ERβ). Additionally, it binds to G Protein-coupled Estrogen Receptor (GPER), which allows it to quickly cause effects in cells.
How Estradiol Cypionate works in the bodyEstradiol is a hormone that enters cells and binds to a receptor. When it does this, it triggers a series of reactions in the cell. These reactions cause the cell to produce proteins that produce the effects of estradiol on the body. These effects include increased production of certain proteins in the blood, as well as reduced levels of certain hormones. These changes help to reverse some of the symptoms of menopause and low estrogen levels.

When to interrupt dosage

The recommended dosage of Estradiol Cypionate is contingent upon the diagnosed condition, including Low Testosterone, hypoestrogenism and Menopause. The measure of dosage varies, in line with the administration system enumerated in the table below.
Condition
Dosage
Administration
Low Testosterone
, 5.0 mg/mL, 50.0 mg/mL
, Intramuscular, Injection - Intramuscular, Injection, Injection, suspension, Injection, suspension - Intramuscular
hypoestrogenism
, 5.0 mg/mL, 50.0 mg/mL
, Intramuscular, Injection - Intramuscular, Injection, Injection, suspension, Injection, suspension - Intramuscular
Menopause
, 5.0 mg/mL, 50.0 mg/mL
, Intramuscular, Injection - Intramuscular, Injection, Injection, suspension, Injection, suspension - Intramuscular
moderate Menopausal Vasomotor Symptoms
, 5.0 mg/mL, 50.0 mg/mL
, Intramuscular, Injection - Intramuscular, Injection, Injection, suspension, Injection, suspension - Intramuscular

Warnings

There are 20 known major drug interactions with Estradiol Cypionate.
Common Estradiol Cypionate Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Estradiol cypionate.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Estradiol cypionate.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Estradiol cypionate.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Estradiol cypionate.
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol cypionate.
image of a doctor in a lab doing drug, clinical research

Estradiol Cypionate Novel Uses: Which Conditions Have a Clinical Trial Featuring Estradiol Cypionate?

19 active clinical trials are currently assessing the potential of Estradiol Cypionate to alleviate hypoestrogenism, Low Testosterone and Menopause Symptoms.
Condition
Clinical Trials
Trial Phases
hypoestrogenism
1 Actively Recruiting
Phase 4
Menopause
0 Actively Recruiting
moderate Menopausal Vasomotor Symptoms
0 Actively Recruiting
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1

Estradiol Cypionate Reviews: What are patients saying about Estradiol Cypionate?

5Patient Review
5/27/2013
Estradiol Cypionate for Low Estrogen After Operation to Remove Ovaries
I switched from Valerate to Cypionate and saw much better results after the second injection. The half-life curve is smoother and more constant, which nearly eliminated the severe mood swings I experienced on Valerate.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about estradiol cypionate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much does estradiol cypionate cost?

"The cost of Depo-Estradiol intramuscular solution (cypionate 5 mg/mL) is approximately $157 for a 5 mL supply, depending on the pharmacy you visit."

Answered by AI

Which is better estradiol valerate or cypionate?

"Estradiol cypionate produces lower, later, and longer peak levels than estradiol valerate, but the average blood levels and effects on the body should be the same."

Answered by AI

What is estradiol cypionate used for?

"This medication may also be used to prevent osteoporosis (weak bones) after menopause.

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause caused by the body making less estrogen, such as hot flashes and vaginal dryness. This medication may also be used after menopause to prevent osteoporosis (weak bones)."

Answered by AI

Clinical Trials for Estradiol Cypionate

Image of ICON Early Phase Services, LLC_Clinic San Antonio in San Antonio, United States.

Follitropin Alfa for Male Infertility

18 - 45
Male
San Antonio, TX
The purpose of this study is to assess the bioequivalence of Test and Reference in healthy downregulated male participants. This is a 2-sequence, 2-period study using the following treatment sequences across Study Periods 1 and 2. At the end of the first Downregulation period (DR1), eligible participants will be randomly assigned to 1 of the 2 treatment sequences: Sequence 1: Test - Reference Sequence 2: Reference - Test Where, Test = follitropin alfa (solution for injection in prefilled pen), and Reference = follitropin alfa (powder and diluent for solution for injection in vial). The total duration of the study will be up to approximately 9 weeks.
Phase 1
Recruiting
ICON Early Phase Services, LLC_Clinic San AntonioMedical ResponsibleEMD Serono Research & Development Institute, Inc.
Image of Neuromuscular Research Laboratory in Pittsburgh, United States.

Hormone Therapy for Musculoskeletal Health

18 - 40
All Sexes
Pittsburgh, PA
Non-combat-related muscle, tendon and bone injuries are the most common injuries suffered by military personnel, particularly in new recruits. These injuries impact military readiness and are responsible for roughly 60% of limited duty days, 65% of soldiers who are unable to deploy, and nearly $500 million in medical cost to the government annually in the Army alone. Drug interventions must be studied and developed to prevent these negative outcomes and prepare military personnel for the demands of military service. At the current time, military leadership has identified critical gaps in understanding how to minimize these injuries and train soldiers with drug intervention serving among those gaps. The goal of this study is to determine how a hormonal intervention can change muscle, tendon, and bone function as well as physical and psychological performance in response to mental and physical stress. To do so, we will examine sex hormone (testosterone, estrogen) levels, muscle, tendon, and bone images, blood samples, and physical and mental performance. We will look at things like changes in hormone levels, chemicals released from active skeletal muscles, and your body composition. The results from this study will be used to improve physical readiness training in the military with the goal of reducing injuries.
Phase 4
Recruiting
Neuromuscular Research LaboratoryBradley C Nindl, PhD
Image of University of Colorado Anschutz Medical Campus in Aurora, United States.

Estradiol Patch for Menopause

20 - 45
Female
Aurora, CO
The menopause transition is associated with a decrease in artery health and an increased risk for weight gain in storing fat in the stomach area which may increase the risk for heart disease. The purpose of this research is to study how the decrease in estrogen at menopause changes artery health and fat gain, and risk of disease in women as they age. The first aim in this study will determine whether short term and long term low estrogen levels in premenopausal women decreases artery function and whether this is related to an increase in fat in the stomach area. The second aim will determine whether the changes in artery health and body fat are related to changes in a pathway that breaks down an important amino acid called tryptophan. This pathway is thought to play a role in regulating the aging process. Therefore, the investigators will determine whether the decrease in artery health and the increase in body fat in the stomach region with low estrogen is related to changes in this pathway in the blood, in vascular cells and fat tissue. Because estrogen levels fluctuate in premenopausal women, the investigators will use an approach (intervention) that controls estrogen levels to address these aims. The investigators will use a medication that is typically used to treat endometriosis or uterine fibroids to lower estrogen levels and an estrogen patch to increase estrogen in some women. Some women will receive a patch that has no estrogen (called a placebo patch). The intervention period will be 20 weeks. The study will provide us with new knowledge on how low estrogen with menopause affects artery health and fat gain estrogen.
Phase 4
Recruiting
University of Colorado Anschutz Medical CampusKerrie Moreau, PhD
Have you considered Estradiol Cypionate clinical trials? We made a collection of clinical trials featuring Estradiol Cypionate, we think they might fit your search criteria.Go to Trials
Image of North Florida/South Georgia Veterans Health System in Gainesville, United States.

Locomotor Training + Testosterone for Spinal Cord Injury

18+
Male
Gainesville, FL
This pilot study will determine the feasibility of implementing a combinatory rehabilitation strategy involving testosterone replacement therapy (TRT) with locomotor training (LT; walking on a treadmill with assistance and overground walking) in men with testosterone deficiency and walking dysfunction after incomplete or complete spinal cord injury. The investigators hypothesize that LT+TRT treatment will improve muscle size and bone mineral density in men with low T and ambulatory dysfunction after incomplete or complete SCI, along with muscle fundtion and walking recovery in men with T low and ambulatory dysfunction ater incomplete SCI.
Phase 2
Recruiting
North Florida/South Georgia Veterans Health System (+1 Sites)Dana M Otzel, Phd
Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Testosterone Therapy for Low Testosterone and Diabetes

35 - 70
Male
Houston, TX
Low testosterone and diabetes mellitus are each associated with increased risk for fractures. Men with diabetes mellitus are commonly found to have low testosterone as well. Testosterone has been shown to improve the bone health of patients with low testosterone but has not been tested in patients who also have diabetes mellitus in addition to low testosterone. To date, there is no treatment that is specifically recommended for bone disease among patients with diabetes. This study will evaluate the effect of testosterone on the bone health of male Veterans who have both diabetes and low testosterone, both of which are highly prevalent in this subset of the population.
Phase 4
Waitlist Available
Quick Reply
Michael E. DeBakey VA Medical Center, Houston, TXReina C. Villareal, MD
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security